- Home
- NTAP vs INCY Comparison
NTAP vs INCY Comparison
Compare NTAP & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTAP | INCY |
|---|---|---|
| Founded | 1992 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 17.0B |
| IPO Year | 1995 | 1993 |
Fundamental Metrics
Financial Performance| Metric | NTAP | INCY |
|---|---|---|
| Price | $95.38 | $100.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 20 |
| Target Price | ★ $121.15 | $97.78 |
| AVG Volume (30 Days) | ★ 2.6M | 2.0M |
| Earning Date | 02-26-2026 | 02-10-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | 5.78 | ★ 3878.02 |
| EPS | 5.75 | ★ 5.90 |
| Revenue | ★ $6,637,000,000.00 | $4,813,105,000.00 |
| Revenue This Year | $4.99 | $19.64 |
| Revenue Next Year | $4.86 | $10.98 |
| P/E Ratio | ★ $16.95 | $17.39 |
| Revenue Growth | 2.53 | ★ 18.09 |
| 52 Week Low | $71.84 | $53.56 |
| 52 Week High | $127.78 | $112.29 |
Technical Indicators
Market Signals| Indicator | NTAP | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 33.63 | 47.03 |
| Support Level | $97.16 | $99.28 |
| Resistance Level | $100.58 | $105.06 |
| Average True Range (ATR) | 2.93 | 3.27 |
| MACD | -0.24 | -0.53 |
| Stochastic Oscillator | 9.17 | 24.25 |
Price Performance
Historical ComparisonAbout NTAP NetApp Inc.
NetApp Inc is a provider of enterprise data management and storage solutions. The company's segments include Hybrid Cloud and Public Cloud. It generates maximum revenue from the Hybrid Cloud segment. The Hybrid Cloud segment offers a portfolio of storage management and infrastructure solutions that help customers recast their traditional data centers with the power of the cloud. This portfolio is designed to operate with public clouds to unlock the potential of hybrid, multi-cloud operations. Hybrid Cloud is composed of software, hardware, and related support, as well as professional and other services. Geographically, the company generates the majority of its revenue from the United States, Canada and Latin America (Americas).
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.